Afrezza

About MannKind

MannKind Corporation has evolved from a development-stage entity into a commercial organization with a diversified portfolio anchored by its proprietary Technosphere® inhalation platform. The company's strategy combines the commercialization of its own products—Afrezza® (inhaled insulin) and V-Go®—with strategic partnerships, as evidenced by the success of Tyvaso DPI®, and targeted acquisitions like scPharmaceuticals (FUROSCIX®). With a focus on cardiometabolic and orphan lung diseases, MannKind aims to drive growth through label expansions, pediatric studies, and leveraging its validated platform for new therapeutic applications.

About MannKind

MannKind Corporation has evolved from a development-stage entity into a commercial organization with a diversified portfolio anchored by its proprietary Technosphere® inhalation platform. The company's strategy combines the commercialization of its own products—Afrezza® (inhaled insulin) and V-Go®—with strategic partnerships, as evidenced by the success of Tyvaso DPI®, and targeted acquisitions like scPharmaceuticals (FUROSCIX®). With a focus on cardiometabolic and orphan lung diseases, MannKind aims to drive growth through label expansions, pediatric studies, and leveraging its validated platform for new therapeutic applications.

About MannKind Corp

MannKind Corporation has evolved from a development-stage enterprise into a multi-product biopharmaceutical company with a core mission of transforming chronic disease management through innovative, patient-centric inhaled solutions. Its competitive moat is anchored in the proprietary Technosphere® drug delivery platform, which has enabled the commercialization of Afrezza® and underpins a diversified portfolio and partnership strategy. The company is now demonstrating strong commercial execution, with FY2025 revenues reaching $349 million, driven by growth in its core products and strategic acquisitions like scPharmaceuticals.

About MannKind Corp

MannKind Corporation has evolved from a development-stage enterprise into a multi-product biopharmaceutical company with a core mission of transforming chronic disease management through innovative, patient-centric inhaled solutions. Its competitive moat is anchored in the proprietary Technosphere® drug delivery platform, which has enabled the commercialization of Afrezza® and underpins a diversified portfolio and partnership strategy. The company is now demonstrating strong commercial execution, with FY2025 revenues reaching $349 million, driven by growth in its core products and strategic acquisitions like scPharmaceuticals.

Therapeutic Areas